Retatrutide is currently available as a research peptide while awaiting formal regulatory approval, offering an accessible alternative for those who want to explore the most advanced option before it reaches the pharmaceutical market
Yanase F, Tosif SH, Churilov L, Yee K, Bellomo R, Gunn K, Kim C, Krizhanovskii C, Hahn RG, Riedel B, Weinberg L
It is able to bind to GIP receptors with almost 9 times greater affinity than the endogenous hormone, while its affinity for GLP-1R and GCGR is lower than that of their corresponding hormones
Visit the FAQs page or send us a chat message
Ortmeyer, H
Your shopping cart has This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service